Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CluePoints Cited in New FDA Guidance for Improved Data Quality

Published: Wednesday, August 14, 2013
Last Updated: Wednesday, August 14, 2013
Bookmark and Share
CSM techniques have been cited by the FDA in the recent release of the final guidance document detailing the agency's stance on the "Oversight of Clinical Investigations".

The guidance advocates the use of central monitoring to ensure the quality of clinical trial data and cites two papers written by the architects of CluePoints’ intelligent statistical algorithms that describe how these techniques can be used to effectively detect anomalies, and help improve the effectiveness of on-site monitoring by prioritizing site visits using central statistical data checks.1 

The new FDA guidance describes how central monitoring methodologies should be used, where appropriate, to oversee studies and effectively monitor clinical investigations to protect subjects and enhance the quality of research. The FDA also states that the previously preferred approach for regular on-site monitoring with 100% Source Data Verification (SDV) is no longer called for, particularly due to new technological advances that make it possible to monitor data quality more efficiently.

Not only do the CSM techniques offered by CluePoints play a crucial role in Risk-Based Monitoring, but they are used even more generally as part of a sponsor’s risk-mitigation strategy as they are extremely efficient at identifying data anomalies and, consequently, enhancing the quality of the final submission. Larger pharma sponsors are taking the clinical oversight advantage a stage further and are using CluePoints to ensure that their strategic outsourcing programs are not just getting them to database lock on-time and on budget, they are also safe in the knowledge that the quality and integrity of their clinical data is beyond reproach. They are running regular analyses of the clinical data throughout the study and charging their partners with taking corrective actions as discrepancies are identified.

The resulting efficiencies from undertaking CSM to target the sites identified ‘at risk’ are now being successfully harnessed by many sponsors and CROs alike. The savings that sponsors will enjoy from a comprehensive Central Monitoring approach will no doubt be significant in the medium-term, but even today sponsors can experience tangible cost benefits by reducing on-site monitoring efforts through targeting those sites that are deemed to be outliers using advanced statistical techniques to analyze the clinical trial data.

Marc Buyse, Founder of CluePoints commented, “This is a major step forward for our industry and one that all sponsors should embrace. The opportunity to improve data quality and integrity, while mitigating risk, is the outcome that everyone wants and the agency is encouraging an approach that not only does this but offers companies the opportunity to increase efficiencies and, ultimately, save a lot of money. CluePoints is delighted to be at the forefront of this initiative and is available to consult with anyone who is interested in the practical application of these techniques based on proven and validated experience to date”.

Francois Torche, CEO, CluePoints, says, “The agency’s guidance is recognition of an approach that the CluePoints team has been working towards for a number of years. We have a talented and enthusiastic group of experts that have been assisting sponsors to implement various approaches to Risk-Based Monitoring and the final guidance is a very close match to our overall vision. Subjective Key Risk Indicators based on operational metrics are of value but there is no doubt that an objective assessment of data quality is crucial to managing regulatory risk and ultimately reducing costs”.

Please see below for copies of the papers on Central Statistical Monitoring that are referenced in the FDA Guidance for Industry “Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring” for the guidance itself.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CluePoints Strengthens and Expands Global Team
Company announces new board and business development appointments.
Wednesday, February 26, 2014
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!